ECSP099536A - METHODS AND FORMULATIONS FOR IMPROVED BIODISPONIBILITY OF ANTIPROGESTINES - Google Patents

METHODS AND FORMULATIONS FOR IMPROVED BIODISPONIBILITY OF ANTIPROGESTINES

Info

Publication number
ECSP099536A
ECSP099536A EC2009009536A ECSP099536A ECSP099536A EC SP099536 A ECSP099536 A EC SP099536A EC 2009009536 A EC2009009536 A EC 2009009536A EC SP099536 A ECSP099536 A EC SP099536A EC SP099536 A ECSP099536 A EC SP099536A
Authority
EC
Ecuador
Prior art keywords
antiprogestines
formulations
methods
improved
biodisponibility
Prior art date
Application number
EC2009009536A
Other languages
Spanish (es)
Inventor
Joseph Podolski
Original Assignee
Repros Therapeutis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutis Inc filed Critical Repros Therapeutis Inc
Publication of ECSP099536A publication Critical patent/ECSP099536A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere en términos generales a composiciones con biodisponibilidad mejorada que comprenden por lo menos una antiprogestina. Más particularmente, la invención presente se relaciona con una potente actividad antiporgestacional, actividad antiglucocorticoide mínima y biodisponibilidad mejorada, comprendiendo un derivado de 19-norprogesterona I y opcionalmente un excipiente farmacéuticamente aceptable.The present invention relates in general terms to compositions with improved bioavailability comprising at least one antiprogestin. More particularly, the present invention relates to a potent antiporgestational activity, minimal antiglucocorticoid activity and improved bioavailability, comprising a 19-norprogesterone I derivative and optionally a pharmaceutically acceptable excipient.

EC2009009536A 2006-12-28 2009-07-23 METHODS AND FORMULATIONS FOR IMPROVED BIODISPONIBILITY OF ANTIPROGESTINES ECSP099536A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88242306P 2006-12-28 2006-12-28
US88537207P 2007-01-17 2007-01-17

Publications (1)

Publication Number Publication Date
ECSP099536A true ECSP099536A (en) 2009-08-28

Family

ID=39589194

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009536A ECSP099536A (en) 2006-12-28 2009-07-23 METHODS AND FORMULATIONS FOR IMPROVED BIODISPONIBILITY OF ANTIPROGESTINES

Country Status (14)

Country Link
EP (1) EP2094275A2 (en)
JP (1) JP2010514793A (en)
KR (1) KR20090086470A (en)
AR (1) AR064697A1 (en)
AU (1) AU2007339820A1 (en)
CA (1) CA2672888A1 (en)
CL (1) CL2007003855A1 (en)
CO (1) CO6190605A2 (en)
EA (1) EA200970646A1 (en)
EC (1) ECSP099536A (en)
MX (1) MX2009006912A (en)
NO (1) NO20092271L (en)
TW (1) TW200831110A (en)
WO (1) WO2008083192A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
WO2010119029A1 (en) 2009-04-14 2010-10-21 Laboratoire Hra-Pharma Method for on-demand contraception
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
WO2013059664A1 (en) * 2011-10-21 2013-04-25 Seachaid Pharmaceuticals, Inc. Pharmaceutical compositions and uses thereof
FR2997627B1 (en) * 2012-11-08 2015-01-16 Hra Pharma Lab CO-MICRONIZATION PRODUCT COMPRISING ULIPRISTAL ACETATE
FR2997628B1 (en) * 2012-11-08 2015-01-16 Hra Pharma Lab CO-MICRONIZATION PRODUCT COMPRISING A SELECTIVE MODULATOR OF PROGESTERONE RECEPTORS
FR2999081B1 (en) * 2012-12-06 2015-02-27 Hra Pharma Lab SOLID DISPERSION OF A SELECTIVE PROGESTERONE RECEPTOR MODULATOR
KR20150139919A (en) 2013-04-10 2015-12-14 쁘레글렘 에스아 Progesteron receptor modulators for use in the therapy of uterine fibroids
WO2018106914A1 (en) * 2016-12-09 2018-06-14 Repros Therapeutics Inc. Oral pharmaceutical compositions comprising an unmicronized selective progesterone receptor as active agent
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation
US11878025B2 (en) 2021-09-06 2024-01-23 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2152671T3 (en) * 1996-05-01 2001-02-01 Us Gov Health & Human Serv PROGESTERONE DERIVATIVES REPLACED IN POSITION 21 AS NEW ANTIPROGESTATIONAL AGENTS.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2821555B1 (en) * 2001-03-01 2003-05-16 Besins Int Lab PROGESTIVE CO-MICRONIZED WITH A SURFACTANT, PHARMACEUTICAL COMPOSITION COMPRISING SAME, METHODS OF MAKING SAME AND USES THEREOF
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
US20090149434A1 (en) * 2005-09-29 2009-06-11 Joseph Podolski Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride

Also Published As

Publication number Publication date
WO2008083192A2 (en) 2008-07-10
NO20092271L (en) 2009-08-06
EA200970646A1 (en) 2009-12-30
CL2007003855A1 (en) 2008-03-14
MX2009006912A (en) 2009-08-12
CO6190605A2 (en) 2010-08-19
AU2007339820A1 (en) 2008-07-10
CA2672888A1 (en) 2008-07-10
EP2094275A2 (en) 2009-09-02
JP2010514793A (en) 2010-05-06
KR20090086470A (en) 2009-08-12
WO2008083192A8 (en) 2009-07-09
AR064697A1 (en) 2009-04-22
TW200831110A (en) 2008-08-01
WO2008083192A3 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
MX2009010289A (en) COMPOSITIONS FOR NASAL ADMINISTRATION.
ZA200807274B (en) Novel pyridine derivatives
NO20076613L (en) Pharmaceutical Formulations and Their Use
MY154909A (en) Novel thiophene derivatives
AU2006243643A8 (en) Pharmaceutical compositions with synchronized solubilizer release
TW200700406A (en) Novel thiophene derivatives
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
BRPI0509184A (en) pharmaceutical compositions
TW200716591A (en) Novel thiophene derivatives
IL188042A (en) Estrogen compositions for vaginal administration
TW200708511A (en) Novel thiophene derivatives
MX2007003342A (en) Compounds for inflammation and immune-related uses.
WO2008073448A3 (en) Pharmaceutical formulations and methods for making the same
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
NO20091846L (en) Macrocyclic peptides as hepatitis C virus inhibitors
WO2005067893A3 (en) Pharmaceutical compositions comprising midazolam in a high concentration
TW200738670A (en) Novel thiophene derivatives
IL186127A (en) Pharmaceutical compositions for treating depression and methods for preparing the same
GT200800107A (en) ORAL FORMULATIONS THAT INCLUDE TIGECICLINE
WO2008103847A3 (en) Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
ATE506340T1 (en) 12-ARYL-PROSTAGLANDIN ANALOGUE
EA200800974A1 (en) COMPOSITIONS WITH IMPROVED BIO-ACCESSIBILITY, CONTAINING STEROID DERIVATIVE AND POLYGLYCOLIZED GLYCERID
CL2009001089A1 (en) Indole-derived compounds [2,1-a] [2] benzacepin; pharmaceutical composition comprising said compound; and use of the compound for the treatment of hepatitis c.
WO2007057748A3 (en) Use of colostrum for the prophylaxis of influenza syndromes